A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate...

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Prostate cancer (PCa) is a significant global health concern for men.
• MicroRNAs are globally downregulated in PCa, particularly in aggressive tumors, with mechanisms largely unknown.
• Investigating epigenetic regulation of microRNAs in PCa is crucial.

Purpose of the Study:

• To identify epigenetically downregulated microRNAs in prostate cancer.
• To elucidate the role of DNA methylation in microRNA dysregulation in PCa.
• To explore the functional impact of identified microRNAs in PCa progression.

Main Methods:

• Combined analysis of microRNA expression and whole-genome DNA methylation data.
• Utilized TCGA dataset for validation of microRNA expression and methylation correlation.
• Performed in vitro functional assays to assess the biological effects of miR-152-3p.

Main Results:

• MiR-152-3p was found to be underexpressed in PCa, correlating with promoter hypermethylation.
• In vitro studies showed miR-152-3p suppresses cell viability and invasion while promoting cell cycle arrest.
• TMEM97 was identified as a novel target gene of miR-152-3p, and it is overexpressed in PCa.

Conclusions:

• A combined approach effectively identifies microRNAs downregulated by aberrant promoter methylation.
• MiR-152-3p downregulation and hypermethylation are prevalent in primary PCa.
• Restoring miR-152-3p function may be a potential therapeutic strategy for PCa by targeting cell viability, cycle, and invasion.